Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 162

The DOI matches its Crossref record.

A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1

Charpentier, Bernard, Rostaing, Lionel, Berthoux, Francois, Lang, Philippe, Civati, Giovanni, Touraine, Jean-Louis, Squifflet, Jean-Paul, Vialtel, Paul, Abramowicz, Daniel, Mourad, Georges, Wolf, Philippe, Cassuto, Elisabeth, Moulin, Bruno, Rifle, Gerard, Pruna, Andr??, Merville, Pierre, Mignon, Fran??oise, Legendre, Christophe, Le Pogamp, Patrick, Lebranchu, Yvon, Toupance, Olivier, Hurault de Ligny, Bruno, Touchard, Guy, Olmer, Michel, Purgus, Raj, Pouteil-Noble, Claire, Glotz, Denis, Bourbigot, Bernard, Leski, Michel, Wauters, Jean-Pierre, Kessler, Mich??le · 2003 · Transplantation

Abstract

BACKGROUND: Induction therapy with antithymocyte globulin (ATG) reduces the incidence of acute rejection after transplantation. A study was undertaken to assess the efficacy and safety of ATG induction on tacrolimus-based and cyclosporine A (CsA)-based therapies compared with immediate tacrolimus triple therapy in kidney transplant recipients. METHODS: In a 6-month, open-label, randomized, prospective study conducted in 30 European centers, 555 renal transplant patients were randomly assigned to tacrolimus triple therapy (Tac triple, n=185), ATG induction with tacrolimus (ATG-Tac, n=186), or ATG induction with CsA microemulsion (ATG-CsA, n=184); all were combined with azathioprine and corticosteroids. The primary endpoint was incidence and time to first acute rejection episode confirmed by biopsy. RESULTS: Patient demographics and clinical parameters at baseline were similar. Patient and graft survival rates were similar in all groups. The incidence of clinically apparent acute rejection was significantly higher (P=0.003) for Tac triple (33.0%) compared with ATG-Tac (22.6%) and the incidence for ATG-Tac was significantly lower (P=0.004) than for ATG-CsA (37.0%). The incidences of acute rejection confirmed by biopsy (primary endpoint) were 25.4%, 15.1%, and 21.2% for Tac triple, ATG-Tac, and ATG-CsA, respectively (Tac triple vs. ATG-Tac, P=0.004). The incidences of corticosteroid-resistant acute rejection were 7.0% (Tac triple), 4.8% (ATG-Tac), and 10.9% (ATG-CsA) (ATG-Tac vs. ATG-CsA, P=0.038). In the ATG groups, the incidences of leukopenia, thrombocytopenia, serum sickness, fever, and cytomegalovirus infection were significantly higher (P<0.05). CONCLUSIONS: Acute rejection was significantly lower in the ATG-Tac group compared with the ATG-CsA and Tac triple groups. Significantly more hematologic and infectious adverse events were observed in both ATG induction groups.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.tp.0000056635.59888.ef

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 162

Metadata

Authors
Charpentier, B., Rostaing, L., Berthoux, F., Lang, P., Civati, G., Touraine, J.-L., Squifflet, J.-P., Vialtel, P., Abramowicz, D., Mourad, G., Wolf, P., Cassuto, E., Moulin, B., Rifle, G., Pruna, A., Merville, P., Mignon, F., Legendre, C., Le Pogamp, P., Lebranchu, Y., Toupance, O., Hurault de Ligny, B., Touchard, G., Olmer, M., Purgus, R., Pouteil-Noble, C., Glotz, D., Bourbigot, B., Leski, M., Wauters, J.-P., & Kessler, M.
Venue
Transplantation
Published
2003-03
Volume
75
Issue
6
Pages
844-851
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2027511687
Cited by
162
References
0
FWCI
2.55
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1. https://app.cochat.ai/papers/10.1097/01.tp.0000056635.59888.ef
The paper
Charpentier, B., Rostaing, L., Berthoux, F., Lang, P., Civati, G., Touraine, J.-L., Squifflet, J.-P., Vialtel, P., Abramowicz, D., Mourad, G., Wolf, P., Cassuto, E., Moulin, B., Rifle, G., Pruna, A., Merville, P., Mignon, F., Legendre, C., Le Pogamp, P., . . . Kessler, M. (2003). A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1. Transplantation. https://doi.org/10.1097/01.tp.0000056635.59888.ef

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.